Case number 1:23-cv-00633
Teva Pharmaceuticals International GmbH et al v. BendaRx USA > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Feb 9, 2024 | 33 | SO ORDERED, re (31 in 1:23-cv-00633-JLH, 35 in 1:23-cv-00490-JLH) Stipulation and Order substituting Defendant BendaRx USA for BendaRx Canada. These actions, C.A. 23-490 and C.A. 23-633, shall be CONSOLIDATED for all purposes. The pending motions to dismiss, C.A. 23-490, D.I. 12 and C.A. 23-633, D.I. 10, are DENIED as moot. Signed by Judge Jennifer L. Hall on 2/9/2024. Associated Cases: 1:23-cv-00490-JLH, 1:23-cv-00633-JLH(ceg) (Entered: 02/09/2024) (6) |
| Feb 8, 2024 | 32 | SO ORDERED, re (34 in 1:23-cv-00490-JLH; 30 in 1:23-cv-00633-JLH) Stipulation and Order to Extend Time for the parties to comply with the Court's Order to February 9, 2024. Signed by Judge Jennifer L. Hall on 2/8/2024. Associated Cases: 1:23-cv-00490-JLH, 1:23-cv-00633-JLH(ceg) (Entered: 02/08/2024) (5) |
| Feb 7, 2024 | 31 | STIPULATION and [Proposed] Order regarding substitution of BendaRx USA for BendaRx Canada by Teva Pharmaceuticals International GmbH. (DiBenedetto, Emily) (Entered: 02/07/2024) (6) |
| Feb 2, 2024 | 30 | STIPULATION TO EXTEND TIME for the parties to comply with the Court's order (D.I. 28) to February 9, 2024 - filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH. (DiBenedetto, Emily) (Entered: 02/02/2024) (5) |
| Jan 30, 2024 | 29 | NOTICE OF SERVICE of Plaintiffs' First Set of Requests for Production to Defendant BendaRx Corp. filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH.(Hoeschen, Nathan) (Entered: 01/30/2024) (2) |
| Jan 25, 2024 | 28 | ORAL ORDER REFERRING MOTION: IT IS HEREBY ORDERED that the Motion to Dismiss for Failure to State a Claim (D.I. 10 ) is now REFERRED to Magistrate Judge Christopher J. Burke. The Court requests that the parties consider consenting to the jurisdiction of Judge Burke to resolve the pending motion; accordingly, IT IS FURTHER ORDERED that, on or before February 2, 2024, the parties shall either (1) submit to the Clerk of Court an executed Form AO 85A Notice, Consent, and Reference of a Dispositive Motion to a Magistrate Judge that sets forth the parties' consent to consideration of the pending motion by a Magistrate Judge; or (2) file a joint letter indicating that both parties do not so consent. The letter should not indicate which party or parties did not consent. Ordered by Judge Jennifer L. Hall on 1/25/2024. (ceg) (Entered: 01/25/2024) (0) |
| Jan 25, 2024 | 27 | Pro Hac Vice Fee - Credit Card Payment received for David I. Berl, Adam D. Harber, Elise M. Baumgarten, Ben Picozzi, and Kathryn Larkin. ( re 26 MOTION for Pro Hac Vice Appearance of Attorney David I. Berl, Adam D. Harber, Elise M. Baumgarten, Ben Picozzi and Kathryn Larkin )( Payment of $ 250, receipt number ADEDC-4322763).(DiBenedetto, Emily) (Entered: 01/25/2024) (0) |
| Jan 25, 2024 | 26 | MOTION for Pro Hac Vice Appearance of Attorney David I. Berl, Adam D. Harber, Elise M. Baumgarten, Ben Picozzi and Kathryn Larkin - filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH. (DiBenedetto, Emily) (Entered: 01/25/2024) (8) |
| Jan 25, 2024 | 25 | SO ORDERED, re 24 Stipulation and Order regarding dismissal of Counts XVII, XVIII, XIX, and XX of Plaintiffs' Complaints. Signed by Judge Jennifer L. Hall on 1/22/2024. (ceg) (Entered: 01/25/2024) (6) |
| Jan 19, 2024 | 24 | STIPULATION and [Proposed] Order regarding dismissal of Counts XVII, XVIII, XIX, and XX of Plaintiffs' Complaints by Cephalon, LLC, Teva Pharmaceuticals International GmbH. (DiBenedetto, Emily) (Entered: 01/19/2024) (6) |
| Aug 22, 2023 | 23 | NOTICE of Subsequent Authority regarding BendaRx Corp.'s Motions to Dismiss by Cephalon, LLC, Teva Pharmaceuticals International GmbH re (12 in 1:23-cv-00490-CFC) MOTION to Dismiss for Failure to State a Claim , (10 in 1:23-cv-00633-CFC) MOTION to Dismiss for Failure to State a Claim (Attachments: # 1 Exhibit 1)(Hoeschen, Nathan) (Entered: 08/22/2023) (0) |
| Jul 21, 2023 | 22 | REDACTED VERSION of 17 Exhibit to a Document by BendaRx Corp.. (Attachments: # 1 Exhibit A, # 2 Exhibit B)(Hunter, Travis) (Entered: 07/21/2023) (0) |
| Jul 20, 2023 | 21 | PROTECTIVE ORDER. Signed by Judge Colm F. Connolly on 7/20/2023. Associated Cases: 1:23-cv-00490-CFC, 1:23-cv-00633-CFC(kmd) (Entered: 07/20/2023) (30) |
| Jul 20, 2023 | 20 | PROPOSED ORDER -- Protective Order (corrected version) by Cephalon, LLC, Teva Pharmaceuticals International GmbH. (Keller, Karen) (Entered: 07/20/2023) (30) |
| Jul 19, 2023 | 19 | PROPOSED ORDER -- Protective Order by Cephalon, LLC, Teva Pharmaceuticals International GmbH. (Keller, Karen) (Entered: 07/19/2023) (30) |
| Jul 14, 2023 | 18 | REDACTED VERSION of 14 Exhibit to a Document by Cephalon, LLC, Teva Pharmaceuticals International GmbH. (DiBenedetto, Emily) (Entered: 07/14/2023) (16) |
| Jul 14, 2023 | 17 | [SEALED] EXHIBIT re 16 Reply Brief Exhibits A and B by BendaRx Corp.. (Attachments: # 1 Exhibit A, # 2 Exhibit B)(Hunter, Travis) (Entered: 07/14/2023) (0) |
| Jul 14, 2023 | 16 | REPLY BRIEF re 10 MOTION to Dismiss for Failure to State a Claim filed by BendaRx Corp.. (Attachments: # 1 Certificate of Compliance, # 2 Exhibit C)(Hunter, Travis) (Entered: 07/14/2023) (0) |
| Jul 14, 2023 | 15 | MOTION for Pro Hac Vice Appearance of Attorney Anne Elise Herold Li, Mark H. Remus, Shannon Lentz, Karla I. Arias and Kassidy Schmitz - filed by BendaRx Corp.. (Freeman, Nathalie) (Entered: 07/14/2023) (7) |
| Jul 7, 2023 | 14 | [SEALED] EXHIBIT re 13 Answering Brief in Opposition, (Exhibits 1-2) by Cephalon, LLC, Teva Pharmaceuticals International GmbH. (Hoeschen, Nathan) (Entered: 07/07/2023) (0) |
| Jul 7, 2023 | 13 | ANSWERING BRIEF in Opposition re 10 MOTION to Dismiss for Failure to State a Claim filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH.Reply Brief due date per Local Rules is 7/14/2023. (Attachments: # 1 Exhibit 3)(Hoeschen, Nathan) (Entered: 07/07/2023) (0) |
| Jun 23, 2023 | 10 | MOTION to Dismiss for Failure to State a Claim - filed by BendaRx Corp.. (Attachments: # 1 Text of Proposed Order, # 2 7.1 Corporate Disclosure Statement)(Hunter, Travis) (Entered: 06/23/2023) (Main Document) (2) |
| Jun 23, 2023 | 11 | OPENING BRIEF in Support re 10 MOTION to Dismiss for Failure to State a Claim filed by BendaRx Corp..Answering Brief/Response due date per Local Rules is 7/7/2023. (Attachments: # 1 Certificate of Compliance)(Hunter, Travis) (Entered: 06/23/2023) (Main Document) (24) |
| Jun 23, 2023 | 12 | NOTICE of Appearance by Nathalie Anne Freeman on behalf of BendaRx Corp. (Freeman, Nathalie) (Entered: 06/23/2023) (1) |
| Jun 23, 2023 | 11 | OPENING BRIEF in Support re 10 MOTION to Dismiss for Failure to State a Claim filed by BendaRx Corp..Answering Brief/Response due date per Local Rules is 7/7/2023. (Attachments: # 1 Certificate of Compliance)(Hunter, Travis) (Entered: 06/23/2023) (Certificate of Compliance) (1) |
| Jun 23, 2023 | 10 | MOTION to Dismiss for Failure to State a Claim - filed by BendaRx Corp.. (Attachments: # 1 Text of Proposed Order, # 2 7.1 Corporate Disclosure Statement)(Hunter, Travis) (Entered: 06/23/2023) (7.1 Corporate Disclosure Statement) (2) |
| Jun 23, 2023 | 10 | MOTION to Dismiss for Failure to State a Claim - filed by BendaRx Corp.. (Attachments: # 1 Text of Proposed Order, # 2 7.1 Corporate Disclosure Statement)(Hunter, Travis) (Entered: 06/23/2023) (Text of Proposed Order) (1) |
| Jun 16, 2023 | 9 | WAIVER OF SERVICE returned executed by Teva Pharmaceuticals International GmbH, Cephalon, LLC: For BendaRx Corp. waiver sent on 6/12/2023, answer due 9/11/2023. (Hoeschen, Nathan) (Entered: 06/16/2023) (1) |
| Jun 15, 2023 | 8 | STANDING ORDER REGARDING BRIEFING IN ALL CASES (nmf) (Entered: 06/15/2023) (2) |
| Jun 14, 2023 | N/A | Case Assigned to Judge Colm F. Connolly. Please include the initials of the Judge (CFC) after the case number on all documents filed. (rjb) (Entered: 06/14/2023) (0) |
| Jun 9, 2023 | 1 | COMPLAINT filed against BendaRx Corp. ( Filing fee $ 402, receipt number ADEDC-4155668.) - filed by Teva Pharmaceuticals International GmbH, Cephalon, LLC, Eagle Pharmaceuticals, Inc. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V, # 23 Exhibit W, # 24 Civil Cover Sheet)(apk) (Entered: 06/12/2023) (Exhibit Q) (3) |
| Jun 9, 2023 | 1 | COMPLAINT filed against BendaRx Corp. ( Filing fee $ 402, receipt number ADEDC-4155668.) - filed by Teva Pharmaceuticals International GmbH, Cephalon, LLC, Eagle Pharmaceuticals, Inc. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V, # 23 Exhibit W, # 24 Civil Cover Sheet)(apk) (Entered: 06/12/2023) (Main Document) (30) |
| Jun 9, 2023 | 1 | COMPLAINT filed against BendaRx Corp. ( Filing fee $ 402, receipt number ADEDC-4155668.) - filed by Teva Pharmaceuticals International GmbH, Cephalon, LLC, Eagle Pharmaceuticals, Inc. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V, # 23 Exhibit W, # 24 Civil Cover Sheet)(apk) (Entered: 06/12/2023) (Exhibit S) (5) |
| Jun 9, 2023 | 1 | COMPLAINT filed against BendaRx Corp. ( Filing fee $ 402, receipt number ADEDC-4155668.) - filed by Teva Pharmaceuticals International GmbH, Cephalon, LLC, Eagle Pharmaceuticals, Inc. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V, # 23 Exhibit W, # 24 Civil Cover Sheet)(apk) (Entered: 06/12/2023) (Exhibit T) (9) |
| Jun 9, 2023 | 1 | COMPLAINT filed against BendaRx Corp. ( Filing fee $ 402, receipt number ADEDC-4155668.) - filed by Teva Pharmaceuticals International GmbH, Cephalon, LLC, Eagle Pharmaceuticals, Inc. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V, # 23 Exhibit W, # 24 Civil Cover Sheet)(apk) (Entered: 06/12/2023) (Exhibit U) (14) |
| Jun 9, 2023 | 1 | COMPLAINT filed against BendaRx Corp. ( Filing fee $ 402, receipt number ADEDC-4155668.) - filed by Teva Pharmaceuticals International GmbH, Cephalon, LLC, Eagle Pharmaceuticals, Inc. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V, # 23 Exhibit W, # 24 Civil Cover Sheet)(apk) (Entered: 06/12/2023) (Exhibit V) (7) |
| Jun 9, 2023 | 1 | COMPLAINT filed against BendaRx Corp. ( Filing fee $ 402, receipt number ADEDC-4155668.) - filed by Teva Pharmaceuticals International GmbH, Cephalon, LLC, Eagle Pharmaceuticals, Inc. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V, # 23 Exhibit W, # 24 Civil Cover Sheet)(apk) (Entered: 06/12/2023) (Exhibit W) (4) |
| Jun 9, 2023 | 1 | COMPLAINT filed against BendaRx Corp. ( Filing fee $ 402, receipt number ADEDC-4155668.) - filed by Teva Pharmaceuticals International GmbH, Cephalon, LLC, Eagle Pharmaceuticals, Inc. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V, # 23 Exhibit W, # 24 Civil Cover Sheet)(apk) (Entered: 06/12/2023) (Civil Cover Sheet) (3) |
| Jun 9, 2023 | 1 | COMPLAINT filed against BendaRx Corp. ( Filing fee $ 402, receipt number ADEDC-4155668.) - filed by Teva Pharmaceuticals International GmbH, Cephalon, LLC, Eagle Pharmaceuticals, Inc. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V, # 23 Exhibit W, # 24 Civil Cover Sheet)(apk) (Entered: 06/12/2023) (Exhibit P) (2) |
| Jun 9, 2023 | 1 | COMPLAINT filed against BendaRx Corp. ( Filing fee $ 402, receipt number ADEDC-4155668.) - filed by Teva Pharmaceuticals International GmbH, Cephalon, LLC, Eagle Pharmaceuticals, Inc. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V, # 23 Exhibit W, # 24 Civil Cover Sheet)(apk) (Entered: 06/12/2023) (Exhibit O) (2) |
| Jun 9, 2023 | 4 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) (SEE ATTACHED PATENT REPORTS) (Attachments: # 1 Patent/Trademark Report, # 2 Patent/Trademark Report)(apk) (Entered: 06/12/2023) (Patent/Trademark Report) (1) |
| Jun 9, 2023 | 4 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) (SEE ATTACHED PATENT REPORTS) (Attachments: # 1 Patent/Trademark Report, # 2 Patent/Trademark Report)(apk) (Entered: 06/12/2023) (Patent/Trademark Report) (1) |
| Jun 9, 2023 | 1 | COMPLAINT filed against BendaRx Corp. ( Filing fee $ 402, receipt number ADEDC-4155668.) - filed by Teva Pharmaceuticals International GmbH, Cephalon, LLC, Eagle Pharmaceuticals, Inc. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V, # 23 Exhibit W, # 24 Civil Cover Sheet)(apk) (Entered: 06/12/2023) (Exhibit N) (2) |
| Jun 9, 2023 | 1 | COMPLAINT filed against BendaRx Corp. ( Filing fee $ 402, receipt number ADEDC-4155668.) - filed by Teva Pharmaceuticals International GmbH, Cephalon, LLC, Eagle Pharmaceuticals, Inc. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V, # 23 Exhibit W, # 24 Civil Cover Sheet)(apk) (Entered: 06/12/2023) (Exhibit M) (2) |
| Jun 9, 2023 | 1 | COMPLAINT filed against BendaRx Corp. ( Filing fee $ 402, receipt number ADEDC-4155668.) - filed by Teva Pharmaceuticals International GmbH, Cephalon, LLC, Eagle Pharmaceuticals, Inc. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V, # 23 Exhibit W, # 24 Civil Cover Sheet)(apk) (Entered: 06/12/2023) (Exhibit L) (22) |
| Jun 9, 2023 | 1 | COMPLAINT filed against BendaRx Corp. ( Filing fee $ 402, receipt number ADEDC-4155668.) - filed by Teva Pharmaceuticals International GmbH, Cephalon, LLC, Eagle Pharmaceuticals, Inc. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V, # 23 Exhibit W, # 24 Civil Cover Sheet)(apk) (Entered: 06/12/2023) (Exhibit K) (28) |
| Jun 9, 2023 | 1 | COMPLAINT filed against BendaRx Corp. ( Filing fee $ 402, receipt number ADEDC-4155668.) - filed by Teva Pharmaceuticals International GmbH, Cephalon, LLC, Eagle Pharmaceuticals, Inc. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V, # 23 Exhibit W, # 24 Civil Cover Sheet)(apk) (Entered: 06/12/2023) (Exhibit J) (30) |
| Jun 9, 2023 | 1 | COMPLAINT filed against BendaRx Corp. ( Filing fee $ 402, receipt number ADEDC-4155668.) - filed by Teva Pharmaceuticals International GmbH, Cephalon, LLC, Eagle Pharmaceuticals, Inc. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V, # 23 Exhibit W, # 24 Civil Cover Sheet)(apk) (Entered: 06/12/2023) (Exhibit I) (18) |
| Jun 9, 2023 | 1 | COMPLAINT filed against BendaRx Corp. ( Filing fee $ 402, receipt number ADEDC-4155668.) - filed by Teva Pharmaceuticals International GmbH, Cephalon, LLC, Eagle Pharmaceuticals, Inc. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V, # 23 Exhibit W, # 24 Civil Cover Sheet)(apk) (Entered: 06/12/2023) (Exhibit H) (30) |
| Jun 9, 2023 | 1 | COMPLAINT filed against BendaRx Corp. ( Filing fee $ 402, receipt number ADEDC-4155668.) - filed by Teva Pharmaceuticals International GmbH, Cephalon, LLC, Eagle Pharmaceuticals, Inc. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V, # 23 Exhibit W, # 24 Civil Cover Sheet)(apk) (Entered: 06/12/2023) (Exhibit G) (28) |
| Jun 9, 2023 | 1 | COMPLAINT filed against BendaRx Corp. ( Filing fee $ 402, receipt number ADEDC-4155668.) - filed by Teva Pharmaceuticals International GmbH, Cephalon, LLC, Eagle Pharmaceuticals, Inc. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V, # 23 Exhibit W, # 24 Civil Cover Sheet)(apk) (Entered: 06/12/2023) (Exhibit F) (30) |
| Jun 9, 2023 | 1 | COMPLAINT filed against BendaRx Corp. ( Filing fee $ 402, receipt number ADEDC-4155668.) - filed by Teva Pharmaceuticals International GmbH, Cephalon, LLC, Eagle Pharmaceuticals, Inc. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V, # 23 Exhibit W, # 24 Civil Cover Sheet)(apk) (Entered: 06/12/2023) (Exhibit E) (29) |
| Jun 9, 2023 | 1 | COMPLAINT filed against BendaRx Corp. ( Filing fee $ 402, receipt number ADEDC-4155668.) - filed by Teva Pharmaceuticals International GmbH, Cephalon, LLC, Eagle Pharmaceuticals, Inc. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V, # 23 Exhibit W, # 24 Civil Cover Sheet)(apk) (Entered: 06/12/2023) (Exhibit D) (30) |
| Jun 9, 2023 | 1 | COMPLAINT filed against BendaRx Corp. ( Filing fee $ 402, receipt number ADEDC-4155668.) - filed by Teva Pharmaceuticals International GmbH, Cephalon, LLC, Eagle Pharmaceuticals, Inc. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V, # 23 Exhibit W, # 24 Civil Cover Sheet)(apk) (Entered: 06/12/2023) (Exhibit C) (28) |
| Jun 9, 2023 | 1 | COMPLAINT filed against BendaRx Corp. ( Filing fee $ 402, receipt number ADEDC-4155668.) - filed by Teva Pharmaceuticals International GmbH, Cephalon, LLC, Eagle Pharmaceuticals, Inc. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V, # 23 Exhibit W, # 24 Civil Cover Sheet)(apk) (Entered: 06/12/2023) (Exhibit B) (30) |
| Jun 9, 2023 | 1 | COMPLAINT filed against BendaRx Corp. ( Filing fee $ 402, receipt number ADEDC-4155668.) - filed by Teva Pharmaceuticals International GmbH, Cephalon, LLC, Eagle Pharmaceuticals, Inc. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V, # 23 Exhibit W, # 24 Civil Cover Sheet)(apk) (Entered: 06/12/2023) (Exhibit A) (26) |
| Jun 9, 2023 | 7 | Summons Issued as to BendaRx Corp. on 6/9/2023. (apk) (Entered: 06/12/2023) (2) |
| Jun 9, 2023 | 6 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Janus Henderson Group PLC, Corporate Parent BlackRock Institutional Trust Company, N.A. for Eagle Pharmaceuticals, Inc. filed by Eagle Pharmaceuticals, Inc. (apk) (Entered: 06/12/2023) (1) |
| Jun 9, 2023 | 5 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Teva Pharmaceutical Industries Ltd., Corporate Parent Cupric Holding Co. LLC for Cephalon, LLC; Corporate Parent Teva Pharmaceutical Industries Ltd., Corporate Parent Capital Research Global Investors for Teva Pharmaceuticals International GmbH filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH. (apk) (Entered: 06/12/2023) (3) |
| Jun 9, 2023 | 4 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) (SEE ATTACHED PATENT REPORTS) (Attachments: # 1 Patent/Trademark Report, # 2 Patent/Trademark Report)(apk) (Entered: 06/12/2023) (Main Document) (1) |
| Jun 9, 2023 | 3 | Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 5/5/2023. Date of Expiration of Patent: SEE ANDA FORM.Thirty Month Stay Deadline: 11/5/2025. (apk) (Entered: 06/12/2023) (2) |
| Jun 9, 2023 | 2 | Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (apk) (Entered: 06/12/2023) (3) |
| Jun 9, 2023 | 1 | COMPLAINT filed against BendaRx Corp. ( Filing fee $ 402, receipt number ADEDC-4155668.) - filed by Teva Pharmaceuticals International GmbH, Cephalon, LLC, Eagle Pharmaceuticals, Inc. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V, # 23 Exhibit W, # 24 Civil Cover Sheet)(apk) (Entered: 06/12/2023) (Exhibit R) (2) |
